Keywords: merck, kgaa, licenses, rights, apitope, ms, drug

Merck KGaA licenses rights to Apitope's MS drug candidate in $203M deal

Article | 19 January 2009

Print This

Germany's Merck KGaA has signed an R&D and commercialization agreement with the UK's Apitope Technology, a wholly-owned subsidiary of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in